Nov 9 (Reuters) - Immutep Ltd (IMM) :
- IMMUTEP REPORTS IMPROVED AND STATISTICALLY SIGNIFICANT SURVIVAL BENEFIT FOR THREE KEY PATIENT GROUPS IN FINAL PHASE IIB AIPAC STUDY RESULTS IN METASTATIC BREAST CANCER
News: IMM Immutep Reports Phase IIb Final AIPAC Study Results
- There are more pages in this discussion • 88 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $534.9M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1600 | 47.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 2712 | 1 |
View Market Depth
| Last trade - 16.16pm 04/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
Day chart unavailable